Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Great Ormond Street Hospital, the most common co-covered peer. At 8, the average consequence score sits above the same-window beat average of 6.4.
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Great Ormond Street Hospital, the most common co-covered peer. At 8, the average consequence score sits above the same-window beat average of 6.4. Source depth averages 3 original sources per story, versus 2.8 across the same-window beat baseline. Esophageal Atresia appears in 1 tracked Biotech story from March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Esophageal Atresia. Shared-story counts are live from our verified record — not editorial picks.
Regulatory Review
Target window for potential FDA/EMA orphan drug or breakthrough device designation filing.
Expanded Trials
Anticipated commencement of multi-center trials for broader pediatric applications.
Phase I Clinical Data
Expected release of initial safety data from first-in-human pilot studies.
Breakthrough Announced
First successful development of a lab-grown oesophagus for pediatric use is reported.
A groundbreaking medical milestone has been achieved with the development of the first lab-grown oesophagus, offering a transformative treatment for children born with rare congenital conditions. This regenerative medicine breakthrough uses tissue engineering to create functional organs, potentially replacing invasive surgeries that currently rely on repositioning other digestive organs.
Esophageal Atresia is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
